Strengthening the Regenerative Medicine Business Through the Acquisition of a Medical Collagen Business
First written in FY2021. 3 of 4 entries say "Advanced", first in FY2022. Latest entry: FY2026.
2 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「With the aim of applying collagen as a raw material in medical devices, we are conducting applied research and development on high-concentration collagen with high-precision formability through joint research with academia and companies. We are also continuing to develop collagen for research reagents.」
The company is continuing applied research and development of high-concentration collagen for medical devices and development of collagen for research reagents through joint research with academia and companies. - FY2023AdvancedAnnual report
「In addition, we expect the regenerative medicine-related market to continue expanding, and our sales in this area are also continuing to grow. In addition to developing new extracellular matrix-related products, we will pursue the development and further sales expansion of reagents such as medical gelatin and medical collagen.」
The company confirmed sales growth for regenerative medicine-related products and identified the development and expanded sales of extracellular matrix, medical gelatin and medical collagen products as specific measures for further strengthening the business. - FY2022AdvancedAnnual report
「We have entered the regenerative medicine field. Going forward, we will focus on making this field one of our core businesses.」
Against the backdrop of the acquisition of the medical collagen business, the company stated its policy of making the regenerative medicine field one of its future core businesses. In research and development, it is developing medical collagen, gelatin and cell culture-related products. - FY2021First statedAnnual report
「To strengthen the regenerative medicine business, on 5 March 2021 we acquired the medical collagen business operated by the Central Research Institute of NH Foods Ltd.」
The company acquired the medical collagen business operated by the Central Research Institute of NH Foods Ltd. and expanded its business platform to make the regenerative medicine field one of its future core businesses.